Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00744640

Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma (GEMOXEL)

Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients With Advanced Pancreatic Adenocarcinoma (APC): A Phase I/II Study

Sponsor: Roche Pharma AG

Conditions Locally Advanced Pancreatic Cancer Metastatic Pancreatic Cancer

Interventions gemcitabine, oxaliplatin, capecitabine

Updated 5 times since 2017 Last updated: Jan 11, 2010 Started: Oct 31, 2005 Primary completion: Feb 28, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Locally Advanced Pancreatic Cancer and Metastatic Pancreatic Cancer, this trial is completed. The trial is conducted by Roche Pharma AG and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roche Pharma AG
Sanofi
Swiss Cancer League
Swiss National Science Foundation
University Hospital, Basel, Switzerland

Data source: University Hospital, Basel, Switzerland

For direct contact, visit the study record on ClinicalTrials.gov .

Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma (GEMOXEL)

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials